Zobrazeno 1 - 10
of 2 691
pro vyhledávání: ''
Autor:
Anna Paisiou, Ioanna Athanasiadou, Georgia Valsami, M Kitra, H.A. Archontaki, Aristides Dokoumetzidis, K. Zisaki, Efthymios Neroutsos, Panagiotis Tsirigotis, Evgenios Goussetis, A Spyridonidis, Stelios Grafakos
Publikováno v:
Journal of Pharmacy and Pharmacology. 73:1340-1350
Objectives To apply therapeutic drug monitoring and dose-individualization of intravenous Busulfan to paediatric patients and evaluate the impact of syringe-pump induced Busulfan infusion lag-time after in vitro estimation. Methods 76 children and ad
Autor:
Ting Xu, Qiong Hua, Haolan Lu, Wael A. Harb, John Gong, Cody J. Peer, Yue He, Siying Xu, David T.L. Liu, Ruiping Dong, Kyriakos P. Papadopoulos, Ni Lu
Publikováno v:
Oncologist
Lessons Learned Subcutaneous injection was an effective route of administration for envafolimab with a favorable pharmacokinetic profile in patients with previously treated advanced solid tumors. Subcutaneous envafolimab was well tolerated and had du
Autor:
Leon Earl Gray, Nicola Evans, Christy S. Lambright, Bethany R. Hannas, Justin M. Conley, Johnathan Furr, Hunter Sampson, Vickie S. Wilson, Paul M. D. Foster
Publikováno v:
Toxicol Sci
Previously, we demonstrated that exposure to some diortho-phthalate esters during sexual differentiation disrupts male reproductive development by reducing fetal rat testis testosterone production (T Prod) and gene expression in a dose-related manner
Publikováno v:
International Journal of Neuropsychopharmacology
Background Negative symptoms are a core aspect of psychopathology in schizophrenia. Currently available pharmacological agents have proven minimally efficacious for remediating negative symptoms. A promising treatment avenue is the intranasal adminis
Autor:
Karina Maslova, A. Praestgaard, H. Leher, Gerd R Burmester, Roy Fleischmann, Mark C. Genovese
Publikováno v:
Rheumatology. 60:4991-5001
Objective The objective of this study was to evaluate the long-term safety and efficacy of sarilumab over 5 years in patients with RA refractory to TNF inhibitors (TNFis). Methods Patients in the 24-week randomized controlled trial (RCT) TARGET (NCT0
Autor:
Raj Tummala, Shiliang Wang, Lorin Roskos, Bing Wang, Linda Santiago, Denison Kuruvilla, Yen Lin Chia
Publikováno v:
Rheumatology. 60:5854-5862
Objectives The randomized, double-blind, phase 2 b MUSE study evaluated the efficacy and safety of the type I IFN receptor antibody anifrolumab (300 mg or 1000 mg every 4 weeks) compared with placebo for 52 weeks in patients with chronic, moderate to
Publikováno v:
Rheumatology. 60:5517-5526
Objective To assess the risk of flare and damage accrual after discontinuation of low-dose glucocorticoids (GCs) in SLE. Methods We performed a comprehensive literature search of the PubMed, Embase, Cochrane Library and Scopus databases from inceptio
Autor:
Anushri Somavarapu, Glory Florence Meejuru, Lakshmi Sudeepthi Nissankara Roa, Ravi Chandra Sekhara Reddy Danduga, Phani Kumar Kola
Publikováno v:
Journal of Pharmacy and Pharmacology. 73:522-534
Objectives This study aimed to evaluate the effect of duloxetine (10 and 20 mg/kg) against chronic immobilisation stress (CIS)-induced anxiety, depression, cognitive impairment and neurodegeneration in mice. Methods CIS, 2 h/10 days (11:00 AM–1:00
Autor:
Richard L. Stouffer, Cecily V. Bishop, J.K. Rodrigues, Maralee S. Lawson, Shally N. Wolf, Alison Y. Ting, Fuhua Xu, Jing Xu, Olena Y. Tkachenko
Publikováno v:
Biol Reprod
Insulin-like growth factors (IGFs) are known for their involvement in endocrine and paracrine regulation of ovarian function. Although IGF2 is the predominant circulating and intraovarian form of IGFs in primate species, the stage-specific follicular
Autor:
Chia-Chi Lin, Shang Yin Wu, Her Shyong Shiah, Hui Jen Tsai, Kwang Yu Chang, Chia Jui Yen, Wu Chou Su, Jang Yang Chang, Ching Chiung Wang, Li-Tzong Chen, Nai Jung Chiang
Publikováno v:
Oncologist
Lessons Learned SCB01A is a novel microtubule inhibitor with vascular disrupting activity. This first-in-human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity. SCB01A is safe and well tolerated in patients with